Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities

A series of N-phenylindoline-5-sulfonamide derivatives was designed, synthesized, and evaluated as novel acyl CoA:monoacylglycerol acyltransferase-2 inhibitors for the treatment of obesity and metabolic disorders.118